Does Losartan Help People Lose Weight by Activating Brown Fat? What the 2026 Study Found
Bottom line: No human weight-loss effect was established. A study published in Nature on 14 October 2026, and described by the US National Institutes of Health the same day, connected use of some angiotensin receptor blockers (ARBs) with detectable brown fat in patient records. Researchers then tested losartan in brown-fat cells and mice. They did not run a clinical trial showing that people taking losartan lose weight, develop more brown fat, or prevent disease.
What was the human part of the study?
The team examined existing PET-CT scans and clinical records from 101,243 adults at a US cancer center. Brown adipose tissue—fat that can use energy to generate heat—was detected in 8,897 of them. An AI-assisted method estimated its activity in a subset. Brown-fat presence and activity were associated with more favorable measures of some cardiometabolic conditions. The records also showed that ARB use, including losartan use, was associated with brown-fat detection.
These comparisons do not show what happened to the same patient after starting losartan. People taking different medicines can differ in their diagnoses, treatments and other characteristics. The researchers adjusted for several factors, but the retrospective design cannot rule out remaining confounding or establish that the drug caused the observed association.
What did the experiments add?
In cultured brown-fat cells, losartan increased markers and measurements related to heat production. In mice, it raised energy expenditure under the tested conditions. The mice did not show a reduction in body weight or fat mass. These experiments support a possible biological mechanism; they do not measure the clinical benefit or safety of using losartan to activate brown fat in humans.
Should this change a blood-pressure prescription?
Not on this evidence alone. Losartan remains a blood-pressure medicine, and this paper does not establish a new weight-loss indication or a reason to choose it over another medicine for weight management. A prospective human study would need to test whether the proposed effect occurs at real-world doses and whether it improves outcomes that matter to patients. Medication decisions depend on a person’s blood pressure, other conditions and treatment history and should be reviewed with a clinician.
Where the finding applies—and where it does not
- Publication date: NIH release and original Nature article, 14 October 2026.
- Population: adults scanned at one US cancer center, not a representative sample of everyone taking blood-pressure medication.
- Study types: retrospective human associations plus cell and mouse proof-of-concept experiments; no randomized human weight-loss trial.
- Limit: PET-CT detection may miss some brown fat, and cancer or cancer treatment may affect the observed patterns. No change to drug approval or South Korean treatment guidance follows from this paper.
Written by: Life Choice Note, an independent health-information explainer. Primary sources reviewed: 17 October 2026. This is not personal medical advice.